All News
Several Studies Addressed Treatment of Axial Spondylitis
Monday afternoon's session on the treatment of Axial Spondyloarthritis presented us with a great selection of studies addressing important issues in modern treatment paradigm of AxSpA.
Read ArticleTRIPLE Trial Results
Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect.
Read ArticleEmerging Trends in the Treatment of Rheumatoid Arthritis
Factors That Contribute to Uveitis in SpA
We know that uveitis is an extra-articular manifestation of SpA but what remains unclear is if there are any factors that may play a role in the development of uveitis. One group sought to understand these issues.
Read ArticleACR 2018 - Day 1 Report
RheumNow is in Chicago covering the ACR annual meeting. Here are the highlights from Sunday (day one). Be sure to check our complete coverage, including articles, video reports and tweets, at acr18.rheumnow.com.
Read ArticleGout and the Social Determinants of Health
During a fascinating gout session on October 21, Hyon Choi presented an important paper (abstract 874) which used data from the Health Professionals Follow-up Study to try to understand the rapid increase in the incidence of gout in recent decades.
Read ArticleBecause It's Rare Doesn’t Mean It Doesn’t Exist: A Tribute to Relapsing Polychondritis
During medical training, we were taught about rare diseases that are unlikely to be encountered, but there is a reason why our professors even mention these diseases. It is not just for our board exams; the lectures are for us to recognize the features of the disease when the rare patient comes across our exam table.
Read ArticleHigh Dose Flu Vaccine for Patients Younger Than 65?
We are diving head first into flu season and we need to prepare ourselves. Last year we now know that 80,000 Americans died from influenza.
Read ArticleThe Great Debate: Plaquenil - Choosing Safety over Efficacy?
ICI-Induced Inflammatory Arthritis and Shared Epitope Alleles
Immune checkpoint inhibitors (ICI) have changed the hematology/oncology world. However, their AEs from a rheumatologic standpoint are still being evaluated and at this time, genetic risk factors for inflammatory arthritis due to ICI are not well understood. Dr. Cappelli et al evaluated a possible connection with HLA typing at their institution.
Read ArticleThe 16th Annual La Paulee
La Paulee is traditionally the party/feast after harvest and a time when hard work is rewarded with food, fun, and wine. And so it was that evening; after better understanding genes, cytokines, and pathology it was time to have a good time with friends, old and new.
Read ArticleWalking the Tightrope of Treat to Target in Psoriatic Arthritis
In the last few years, new studies have been published examining if early intervention and tight control (TC) of psoriatic arthritis (PsA) disease activity will have the same beneficial outcomes as it does for rheumatoid arthritis (RA).
Read ArticleNurse Led Gout Management Highly Effective
UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.
Read ArticleRheumNow Week in Review – ACR Preview Edition (10.19.18)
Dr. Jack Cush summarizes the news and reports from RheumNow.Com this past week and previews RheumNow activities at the upcoming ACR 2018 meeting in Chicago.
Read ArticleIt's the Genes, Not the Diet that Raises Urate
Researchers from New Zealand find that in contrast with genetic contributions, diet explains very little variation in serum urate levels in the general population.
Read ArticleNEJM Debate on Medical Marijuana for Chronic Pain
This week’s NEJM features a case discussion and debate over whether medical marijuana should be used to treat chronic pain. The debate focuses on a 31-year-old woman with long-standing complex regional pain syndrome in her leg and foot.
Read ArticleUpdate on Immune Checkpoint Inhibitor Toxicity
JAMA has a 2018 update/review of the safety issues seen with mmune checkpoint inhibitors (ICIs) - important new cancer therapies, with 14 cancer indications, that have significantly improved survival in several. ICIs are monoclonal antibodies that block inhibitors of T-cell activation and function.
Read ArticleApremilast Succeeds in Scalp Psoriasis
Celgene has announced results from the phase 3 STYLE study, showing apremilast yielding significant improvement in moderate-to-severe scalp psoriasis. STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive apremilast 30 mg twice daily or placebo for the first 16 weeks.
Read ArticleIL-6 for Adult Still's: A New Option?
Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.
Read ArticleHip and Knee Replacements Monitored by Smart Watch
Reuters reports that patients with hip or knee replacements will now be followed for progress using their Apple watches.
Read Article